Autoimmune Diseases  >>  dextromethorphan hydrobromide/quinidine sulfate  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
NCT00050232: Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

Completed
3
96
US
AVP-923
Avanir Pharmaceuticals
Multiple Sclerosis
06/04
06/04
STAR, NCT00573443: Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

Completed
3
326
US, RoW
dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, AVP-923, Nuedexta™, DM 20 mg/ Q 10 mg, DMQ, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, DM 30 mg/ Q 10 mg, Placebo
Avanir Pharmaceuticals, Syneos Health
Pseudobulbar Affect (PBA)
06/09
09/09

Download Options